BACKGROUND: The prognosis of unresectable pancreatic adenocarcinoma is poor. Therefore, the treatment potential of an intratumoral infusional brachytherapy using macroaggregated human albumin in combination with radioactive chromic phosphate [32P] was investigated in this group of patients. METHODS: Seventeen patients with unresectable tumors received intratumoral infusional brachytherapy. Treatment and assessment of response was performed with the aid of ultrasonography. RESULTS: Four patients had complete response with a duration ranging from 2-57 weeks and 5 patients had partial response with a duration ranging from 4-21 weeks, corresponding to an objective response of 53% (9 of 17 patients). Six of these patients were alive 33-57 weeks after treatment. Radiation necrosis was observed in 1 patient after a 19,000-gray cumulative radiation dose and a slight decrease in blood counts was observed in 2 patients. CONCLUSIONS: Intratumoral infusional brachytherapy using radioactive colloidal chromic phosphate has the potential to reduce inoperable pancreatic tumors with few side effects.
BACKGROUND: The prognosis of unresectable pancreatic adenocarcinoma is poor. Therefore, the treatment potential of an intratumoral infusional brachytherapy using macroaggregated human albumin in combination with radioactive chromic phosphate [32P] was investigated in this group of patients. METHODS: Seventeen patients with unresectable tumors received intratumoral infusional brachytherapy. Treatment and assessment of response was performed with the aid of ultrasonography. RESULTS: Four patients had complete response with a duration ranging from 2-57 weeks and 5 patients had partial response with a duration ranging from 4-21 weeks, corresponding to an objective response of 53% (9 of 17 patients). Six of these patients were alive 33-57 weeks after treatment. Radiation necrosis was observed in 1 patient after a 19,000-gray cumulative radiation dose and a slight decrease in blood counts was observed in 2 patients. CONCLUSIONS: Intratumoral infusional brachytherapy using radioactive colloidal chromic phosphate has the potential to reduce inoperable pancreatic tumors with few side effects.
Authors: Alexander Rosemurgy; German Luzardo; Jennifer Cooper; Carl Bowers; Emmanuel Zervos; Mark Bloomston; Sam Al-Saadi; Robert Carroll; Hemant Chheda; Larry Carey; Steven Goldin; Shane Grundy; Bruce Kudryk; Bruce Zwiebel; Thomas Black; John Briggs; Paul Chervenick Journal: J Gastrointest Surg Date: 2008-02-12 Impact factor: 3.452
Authors: Andre Bratanic; Dorotea Bozic; Antonio Mestrovic; Dinko Martinovic; Marko Kumric; Tina Ticinovic Kurir; Josko Bozic Journal: World J Gastrointest Oncol Date: 2021-12-15
Authors: Robbert C Bakker; Marnix G E H Lam; Sebastiaan A van Nimwegen; Antoine J W P Rosenberg; Robert J J van Es; J Frank W Nijsen Journal: J Radiat Oncol Date: 2017-06-24
Authors: Manoop S Bhutani; Jason B Klapman; Richard Tuli; Ghassan El-Haddad; Sarah Hoffe; Franklin C L Wong; Beth Chasen; David R Fogelman; Simon K Lo; Nicholas N Nissen; Andrew E Hendifar; Gauri Varadhachary; Matthew H G Katz; William D Erwin; Eugene J Koay; Eric P Tamm; Ben S Singh; Rutika Mehta; Robert A Wolff; Ashish Soman; Irina M Cazacu; Joseph M Herman Journal: Endosc Ultrasound Date: 2020 Jan-Feb Impact factor: 5.628